Lazard Asset Management
CCCC icon

Lazard Asset Management’s C4 Therapeutics CCCC Stock Holding History

Lazard Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,693
Closed -$81K – 2328
2024
Q4 		$81K Buy
+22,693
New +$113K ﹤0.01% 1861
2024
Q1 		– Sell
-12,375
Closed -$69K – 2083
2023
Q4 		$69K Buy
+12,375
New +$28.2K ﹤0.01% 1803
2023
Q1 		– Sell
-4,685
Closed -$27K – 2315
2022
Q4 		$27K Hold
4,685
– – ﹤0.01% 2066
2022
Q3 		$41K Buy
+4,685
New +$48.6K ﹤0.01% 1877
2022
Q2 		– Sell
-3,834
Closed -$93K – 2396
2022
Q1 		$93K Buy
+3,834
New +$93.1K ﹤0.01% 1425

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Lazard Asset Management's CCCC Position: Q1 2025 in Review

Lazard Asset Management sold out of C4 Therapeutics (CCCC) in Q1 2025, closing a stake of 22,693 shares — an estimated $81K sold.

Lazard Asset Management first reported a position in CCCC in Q1 2022 and held it in 5 quarters. The position peaked at $93K in Q1 2022. 114 funds tracked by Wall St. Rank hold CCCC as of Q1 2025.

  • Lazard Asset Management reported no remaining C4 Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 22,693 C4 Therapeutics shares in Q1 2025, an estimated $81K.
  • Lazard Asset Management first reported a position in C4 Therapeutics in Q1 2022 and held it in 5 quarters.
  • Lazard Asset Management's C4 Therapeutics position peaked at $93K in Q1 2022.
  • 114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.